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The human decidua and placenta form a distinct environment distinguished for its
promotion of immunotolerance to infiltrating semiallogeneic trophoblast cells to enable
successful pregnancy. The maternal-fetal interface also successfully precludes
transmission of most pathogens. This barrier function occurs in conjunction with a
diverse influx of decidual immune cells including natural killer cells, macrophages and T
cells. However, several viruses, among other microorganisms, manage to escape
destruction by the host adaptive and innate immune system, leading to congenital
infection and adverse pregnancy outcomes. In this review, we describe mechanisms of
pathogenicity of two such viral pathogens, Human cytomegalovirus (HCMV) and Zika virus
(ZIKV) at the maternal-fetal interface. Host decidual immune cell responses to these
specific pathogens will be considered, along with their interactions with other cell types
and the ways in which these immune cells may both facilitate and limit infection at different
stages of pregnancy. Neither HCMV nor ZIKV naturally infect commonly used animal
models [e.g., mice] which makes it challenging to understand disease pathogenesis.
Here, we will highlight new approaches using placenta-on-a-chip and organoids models
that are providing functional and physiologically relevant ways to study viral-host
interaction at the maternal-fetal interface.
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INTRODUCTION
Pregnancy is a unique immunological phenomenon in which the semiallogenic fetus is able to grow
in the maternal uterine environment. In order for a successful pregnancy to occur, healthy
placentation is necessary to create an environment that is protective for the developing fetus and
promotes growth. How immune balance is maintained by maternal and fetal cells to promote the
survival of the genetically distinct fetus, while preventing infection by a large number of pathogens,
is yet to be fully elucidated (1). This little understood enigma has been the subject of interest and
research for decades (2).
Fertilization leads to the creation of single celled embryo which undergoes several successive
divisions to form a blastocyst. The blastocyst is made up of two types of cells: the outer trophoblast
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or trophoectoderm (TE) layer forming the placenta and chorion,
and the inner layer or inner cell mass (ICM) forming the embryo
proper and amnion (3). The decidua underlying the embryo is
called the decidua basalis, which composes the maternal side of
the placenta. The maternal-fetal interface is made up of the
maternal decidua and fetally-derived placenta. During
implantation, the blastocyst attaches to the decidualized
endometrium and the outer layer of the blastocyst
differentiates into different lineages. The TE gives rise to
cytotrophoblast cells (CTBs) which follow villous and
extravillous pathways to form the placenta. In the villous
pathway, the mononuclear CTBs fuse, creating multinucleated
syncytiotrophoblasts (STBs) that establish floating villi (FV). The
FV are surrounded by maternal blood, with STBs aiding the
provision of nutrients by enabling gas exchange and exchange of
secreted pregnancy-related hormones (human chorionic
gonadotropin, hCG, human placental lactogen, hPL) at the
maternal-fetal interface. Furthermore, CTBs act as anchoring
villi for the attachment of the embryo to the uterus. The CTBs
present in the cell column of the anchoring villi follow the
extravillous pathway and differentiate into interstitial (iCTBs)
and endovascular extravillous trophoblast cells (eCTBs). The
iCTBs further invade up to the inner third of the myometrium
and eCTBs remodel the spiral arteries in low resistance high
blood flow to provide nutrients to the developing embryo (3–6).
The invasion of trophoblast cells at the maternal-fetal interface
occurs in the presence of a large population of maternal immune
cells (7). This includes 70% decidual Natural Killer (dNK) cells,
20%–25% macrophages, 3%–10% T cells and 1.7% dendritic cells
(8–10). The abundance of decidual cytotoxic T cells and
macrophages can vary through the course of pregnancy (11).
The abundance of NK cells in the decidua during the first
trimester, and through the pregnancy (albeit at lower
abundance), implicates them as an essential element in both
the promotion of an immunotolerant environment and the
control of pathogenic infection during pregnancy (Figure 1).
Thus, the paradoxical maternal-fetal interface is admired for
both its immunotolerance to semiallogeneic trophoblastic
invasion (leading to a successful pregnancy) while remaining
remarkably resilient to pathogenic infections. Nevertheless,
several pathogen, termed TORCH pathogens (described
below), successfully cross the placental barrier and cause
devastating infection in the developing fetus (12). In this
review, we will look at the interactions between decidual
immune cells and specific viral TORCH pathogens and review
known mechanisms which may enable viral pathogenesis within
the placental environment.
TORCH is an acronym defining some of the most common
infections associated with vertical transmission. Initially
described in 1971, this group contained just 4 pathogens;
Toxoplasmosis, Rubella, Cytomegalovirus (CMV) and Herpes
simplex type 1 and 2 (13). Since then this group has been
broadened to comprise a host of other infections including
Listeria monocytogenes, Syphilis, Varicella Zoster virus, Human
immunodeficiency virus (HIV), enteroviruses and parvovirus
B19 (14). Most recently, following the Zika virus (ZIKV)
epidemic in South America resulting in observed congenital
anomalies, this group has been further expanded to include
ZIKV, with some suggesting renaming this group “TORCHZ”
(15). The mechanism by which these “TORCHZ” pathogens are
able to circumvent typical clearance by groups of immune cells
(e.g. NK cells, macrophages and others) has been studied by
many groups over the last few decades in order to elucidate not
only routes of pathogenicity but also roles of immune cells within
this immune-privileged environment (12). It remains to be
proven whether the new emerging viral threat by SARS-COV2
which causes COVID-19 including in pregnant women, will be
included in this group of vertically transmitted pathogens (16).
In this review, we will focus on maternal and fetal
macrophages, T cells, and NK cells and their relationship with
each virus. We will focus on the viruses human Cytomegalovirus
(HCMV) and ZIKV, which are known causes of adverse
pregnancy outcomes and delve into how they interact with
various decidual immune cells to promote their survival and
replication. We will examine the timings of pregnancy that
appear to be most permissive to pathogenic infection by these
viruses and we will look at the role of various immune cells in
this context (Figure 2).
A B
FIGURE 1 | Placental structure and location of decidual immune cells in placental tissues. (A) During the first trimester, decidual NK cells, T cells, and dendritic and
maternal macrophages are located primarily in the decidua basalis, while fetal Hofbauer cells (HCs) are primarily located in the placental villi and fetal membranes.
Cytotrophoblast (CTBs) can be found in both the decidua basalis and placental villi, while syncytiotrophoblasts (STBs) are only found in the placental villi. (B) In term
placentas, location of decidual immune cells is roughly the same, but the number of maternal macrophages and decidual Natural Killer (dNK) cells can be reduced.
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DECIDUAL T CELLS
In the early first term decidua, 3%–10% of resident leukocytes are
T cells with approximately 30%–45% of these T cells being CD4+
(T helper cells) and 45%–75% being CD8+ (cytotoxic) T cells
(17–19). Further studies have estimated the decidual CD4+
population to be comprised of about 50% activated memory
CD25dim T cells and 5% CD4+ CD25bright FOXP3+ Treg cells.
Unlike the peripheral circulation, the decidua has a higher ratio
of CD8+ T cells to CD4+ T cells and an overall higher number of
CD8+ T cells (20). In addition, approximately 40% of the
decidual CD8+ population are effector-memory T cells with
reduced perforin and granzyme B in comparison to their
peripheral counterparts (21). One study published in 2016
described a small percentage of CD8+ T cells found in
uncomplicated term decidua to be viral specific. Though these
populations of viral specific CD8+ T cells were 1.3% and 2.2% in
the decidual basalis and decidual parietalis respectively, they
demonstrated that this was higher than that seen in peripheral
blood and postulated a role for their presence in the decidua as
one of immunoprotection for the fetus. This study could not
conclude upon the origin of these T cells, and whether they were
recruited from the periphery or activated in the decidua. In
addition, more work remains to be done to establish whether
these virus specific CD8+ T cells exist early in pregnancy (22).
Another study has described the presence of a small population
of CD4+ HLA-G+ T cells which are thought to acquire HLA-G
through trogocytosis from decidual dendritic cells. It is thought
that these T cells promote immunotolerance at the maternal-fetal
interface, and they have been shown to be downregulated in
pathologies such as preeclampsia (PE) (23). Therefore, it appears
T cells play specific roles in immunity and tolerance. To this end
we will look at the role that various populations of T cells may
play in either enabling or preventing infection by TORCH
pathogens at the maternal-fetal interface.
MACROPHAGES—MATERNAL
AND FETAL
Macrophages constitute 20-25% of all leukocytes in the first
trimester decidua and play an important role in tissue
remodeling, angiogenesis, host defense and immunotolerance
(24). Macrophages are considered a key link between adaptive
and innate immunity, communicating to other immune cells and
modulating their activity (25, 26). These cells are therefore vital
throughout pregnancy, adapting their phenotype to address the
changing requirements of the evolving decidua (27). Tissue
resident decidual macrophages are thought to be recruited from
monocytes in the peripheral circulation (28). Distinct subtypes of
macrophages have been shown to be present in first-trimester
decidual tissue exhibiting immunomodulatory, proinflammatory,
and tissue remodeling phenotypes and play key roles in protective
immunity as well as fetal tolerance (29). Decidual macrophages are
known for their highly immunosuppressive phenotype at the
maternal-fetal interface, expressing CD206, DC-SIGN and Tim-
3 among other receptor markers (30, 31).
FIGURE 2 | Timing and location of viral infections in the placenta. Human cytomegalovirus (HCMV) is capable of intrapartum infection, as well as postpartum
infection during breastfeeding; it is currently unknown whether Zika virus (ZIKV) is capable of this type of transmission as well. HCMV and ZIKV are both capable of
transplacental infection, with HCMV infection primarily occurring in the 3rd trimester and ZIKV infection is more common in the 1st trimester. CMV and ZIKV infection
additionally cause both intrauterine growth restriction and miscarriage.
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In addition to these maternally derived macrophages exist
fetal-derived macrophages called Hofbauer cells (HCs), which sit
in the stroma of the chorionic villi (32). These HCs are resident
in close proximity to fetal vessels and trophoblast cells from the
first trimester until birth. HCs could serve as a portal of entry for
pathogens from the infected mother (33). Initially during
implantation, they appear to have an inflammatory M1
phenotype which has both microbicidal activity and promotes
a cell-mediated Th1 cytokine response. Later, they shift to a
mixture of both M1 and M2 phenotypes following trophoblastic
invasion and remodeling (34, 35). Several studies have implicated
HCs in host viral interactions. Here, we look at the reciprocal
interactions between HCs, maternal macrophages, and HCMV
and ZIKV.
NK CELLS
The NK cell population in the peripheral circulation is
predominately made up of CD56dim CD16+ cells, which are
believed to have a more cytotoxic phenotype (36).
Approximately 10% of the peripheral circulation is constituted
by CD56bright NK cells, which have a more immunotolerant
phenotype (37). In the decidua, these NK cell proportions are
reversed; 70-80% of the total lymphocytes are CD56bright
CD16- (36). Research has demonstrated a number of dNK
subsets within the CD56+CD16- population. It is believed that
this distinct immunotolerant population is fundamental to the
maintenance of a successful pregnancy, with research postulating
both an ability to enable the semiallogenic fetus to thrive while at
the same time responding to pathogenic infections. These NK
cells reside in the decidua basalis close to invading EVTs and
express specific receptors (e.g. KIR receptors, CD94/NKG2A,
ILT2) to activate or inhibit EVT function (38). This large
population of dNK cells are known to be sustained during the
first and second trimester, with their numbers declining toward
term (11, 39). Despite the unique immunotolerant phenotype
demonstrated by dNK cells, it is evident that this cell population
displays a high level of plasticity, gaining cytotoxic function in
the presence of specific pathogens (39). One way by which this
happens is through activation of dNK cell cytotoxcity via killer
cell Ig-like receptor 2DS1 (KIR2DS1). Reduced expression of this
receptor has been associated with adverse pregnancy outcomes
such as miscarriages and fetal growth restriction and individuals
with increased KIR2DS1 expression have shown better outcomes
post-viral infections (40). We will explore further the role that
NK cells play in specific viral infections in pregnancy
TORCH PATHOGENS
HCMV
Human cytomegalovirus (HCMV) was first described in 1954 by
Margaret Smith, who replicated a virus from two newborn babies
who had died from cytomegalic inclusion disease (CID) (41).
What we now know as HCMV first came to the attention of
Ribbert et al. in 1881, where intranuclear inclusions within large
cells were noted in renal and parotid gland cells of stillborn
fetuses. These inclusions, often described as ‘owl’s eye
inclusions’, were noted to be surrounded by a clear halo (42).
HCMV was identified in the 1950s when Smith, Weller and
Rowe isolated and cultured HCMV from salivary glands,
adenoid tissue and liver biopsies respectively (43, 44).
Mechanisms of vertical transmission of HCMV can either be
transplacental during gestation or transvaginal during
parturition; additionally, there is some evidence for breastmilk
transmission (45). HCMV infection is most likely to occur in the
third trimester, demonstrating a 30% risk of mother to child
transmission in the first trimester compared to a 70% risk in the
third trimester (46–48). Congenital HCMV has been estimated
to affect 5–20 in every 1,000 live births, with 10% of HCMV
positive infants suffering neurological consequences from birth
(49). HCMV infection during pregnancy therefore poses a
substantial risk to the developing fetus, leading to congenital
disease including cerebral abnormalities such as periventricular
calcifications, microcephaly, visual impairment, sensorineural
hearing loss, neurodevelopmental delay and hepatomegaly
(45). Congenital HCMV affects 20,000–40,000 pregnancies
annually in the United States and accounts for 25% of all
incidents of pediatric sensorineural hearing loss (50–52). It is
estimated that the burden of morbidity associated with
congenital HCMV infection is greater than that of other
common congenital pediatric conditions such as down’s
syndrome or fetal alcohol syndrome (53–55). HCMV is also
associated with intrauterine growth restriction and miscarriage.
There is a great need to understand maternal immunity
pathways involved in HCMV infection to develop effective
vaccines (56).
HCMV is associated with asymptomatic infection of most of
the world’s population and subclinical illness in pregnant
mothers. In the US, an estimated 2% of unexposed pregnant
women experience primary infection during pregnancy, resulting
in congenital infection in 32% of cases from this population (53,
57–61). However, vertical transmission of HCMV is not only
seen in mothers with primary infection but also IgG seropositive
mothers, who exhibit a 1% rate of congenital HCMV infection.
Mechanisms of infection have been studied through analysis of
placental tissue from all three trimesters of human gestation. In
placental tissues from those suffering from HCMV, necrosis and
oedema has been noted associated with severity of congenital
disease symptoms. It has also been noted that HCMV infection is
often associated with bacterial coinfection with a potentially
pathogenic synergism (62). HCMV resides in the chorionic
villi, specifically infecting CTBs, STBs and HCs. It is believed
that the ability to travel between STBs in the decidua is key to
HCMV pathogenesis (63). Many studies have explored the role
of the adaptive and innate immune system in HCMV infection.
Below we review established interactions between HCMV and
immune cells (Figure 3).
HCMV and Macrophages
HCMV’s ability to infect different populations of macrophages
has been demonstrated by several studies. HCMV has been
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shown to be sequestered by HCs, with placentas from confirmed
cases of HCMV infection demonstrating significant hyperplasia of
this cell population (64–66). A study investigating vaccine
development showed that when neutralizing antibodies are
produced against HCMV, rates of HCs infection are decreased
(67). A different study utilizing placental explants showed HCMV-
IgG immune complexes to undergo Fc Receptor mediated
transcytosis as a mechanism to traverse the syncytium to CTBs.
HCMV is then taken up by HCs in the placental villi (68).
Furthermore, another study by Loenen et al., supports the idea
that HCMV genes are able to increase FcR expression on infected
cells (69). Another study suggested that HCMV replication in STBs
is upregulated in the presence of macrophages (70) by analyzing
HCMV replication in STBs alone or when infected STBs were
cultured with uninfected placental macrophages. This study also
demonstrated elevated levels of HCMV viral titres in co-cultured
supernatants when compared to those from STBs cultured alone.
This demonstrates that not only do macrophages have the capacity
to be infected by HCMV, but also that they may amplify HCMV
infection of surrounding cells in the decidua. Some studies have
depicted a role for latently infected maternal decidual macrophages
in congenital HCMV infection, describing how microbial infections
or insults in the placenta may reactivate these macrophages and in
turn reactivate HCMV infection (71–73).
HCMV and T Cells
The maternal-fetal interface is unique in respect to allogenic
interactions with CD8+ T cells. EVTs are known to invade the
decidua, evading destruction despite the intrinsic ability of CD8+
T cells to recognize foreign antigen via MHC class I molecules.
As discussed previously, one mechanism by which EVTs are
believed to evade CD8+ T cell recognition is through a lack of
expression of HLA-A and HLA-B, which are key to CD8+
cytotoxic activity. During pregnancy, many viruses have been
shown to upregulate maternal CD8+ T cell activity, leading to
migration of highly differentiated effector memory T cells to the
decidua. Despite many descriptions regarding the role of T cells
in HCMV infection in the fetus and the mother, there are few






FIGURE 3 | Interactions between Cytomegalovirus (CMV) and immune cells at the maternal-fetal interface. (A) Human cytomegalovirus (HCMV)-IgG complexes
undergo FcR mediated transcytosis in the syncytium and infect cytotrophoblast (CTBs); HMCV then goes on to infect Hofbauer cells (HCs) in the placental villi.
(B) HCMV infects HCs, resulting in increased FcR expression. (C) Formation of an immunological synapse between decidual Natural Killer (dNK) cells and HCMV
infected APCs prompts the release of perforin and granzyme into infected APCs and results in increased expression of cytotoxic receptors NKp44 and NKG2C, as
well as other markers of cytotoxicity such as CD16 and CD107a. Furthermore, increased cytotoxicity is accompanied by a reduction in expression of inhibitory
receptors such as NKG2A, KIR2DL1, and KIR2DL4. Interaction between KIR2DS1 present on dNK cells and HLA-C on APCs increases dNK cell cytotoxicity in the
context of HMCV infection. HMCV infection also results in increased expression of HLA-DR, which may increase T cell activation. (D) APCs infected with HCMV
exhibit reduced MHC II expression, which is believed to in turn cause a reduced CD8+ T cell response in cases of vertical transmission. The HCMV protein GpUS2 is
also believed to downregulate MHC II expression and CIITA/JAK/STAT signaling.
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HCMV is thought to limit CD8+ T cell activity through
restriction of MHC class II expression on APCs, which in turn
may prevent activation of CD8+ and CD4+ T cells (69). This is
thought to be mediated through the HCMV protein GpUS2,
which may degrade MHC class II glycoproteins or disrupt
downstream CIITA/JAK/STAT signaling pathways (69).
Crespo et al., in 2016 demonstrated that HCMV did not
induce a significant difference in HLA-G expression on either
JEG-3 cells or primary EVTs. HLA-G expression has been
associated with immunotolerance, and therefore its persistence
despite infection may act to protect infected trophoblast cells
from cytotoxic destruction (40).
Studies looking at the role of T cells in viral infection at the
maternal-fetal interface demonstrated lower T-cell numbers and
response in mothers who vertically transmitted HCMV to their
offspring when compared to infected mothers who did not
transmit HCMV, potentially suggesting an active role for T
cells in vertical HCMV transmission (75).
More specifically, a reduction in the number of CD4+CD45RA
+IFN-g+ Treg cells and CD8+CD45RA+IFN-g+ T cells in mothers
who transmitted HCMV to their fetus was noted when contrasted
with mothers who were HCMV positive but did not transmit the
infection. There was also a measurable blunted T cell response in
HCMV infected mothers who vertically transmitted infection,
compared to infected mothers who did not transmit the virus
(76, 77). In infected mothers, HCMV virus specific T cells have
been shown to be elevated in the final trimester when compared to
uninfected mothers (78).
HCMV and NK Cells
Congenital HCMV infection risk is highest for the fetus in the
third trimester, with a 72% transmission risk compared to a 30%
risk in first trimester (46). This is despite the abundance of
immune cells, specifically NK cells, in early pregnancy. dNK
cells exposed to HCMV infected decidual fibroblasts are known
to alter their phenotype to express higher levels of activating
receptors (such as NKG2D and CD94/NKG2C or NKG2E).
Uniquely, utilizing in vitro studies, it was noted that decidual
NK cells had targeted cytotoxic activity against HCMV infected
autologous decidual fibroblasts and heterologous uninfected
fibroblast cells, but appeared to spare trophoblast cells (79, 80).
This demonstrates a clear cytotoxic effector response by
decidual NK cells to HCMV, switching from their typically
immunotolerant phenotype with high levels of inhibitory
receptor expression (CD94/NKG2A, LIR-1, KIRS), to a cytotoxic
phenotype (79, 80). This group also studied the interaction
between dNK and HCMV-infected cells using HCMV positive
and HCMV negative decidual villous explants. This investigation
revealed through fluorescent staining of dNK cells that co-
localisation of dNK cells to cells throughout the HCMV positive
explant occurred, including synaptic connections which was not
seen in HCMV negative explants. This was thought to suggest that
the dNK cells were unable to connect with uninfected
trophoblasts. This also demonstrates that dNK cells are able to
localize and target HCMV infected cells while sparing fetal derived
semiallogenic trophoblast cells (80).
dNK cells are unique in their function, both contributing to
immunotolerance at the maternal-fetal interface, thereby
enabling invasive trophoblastic activity, as well as controlling
pathogenic infection (81). This is thought to be mediated by
secretion of specific cytokines (79, 82–85). The relatively limited
vertical transmission of HCMV during the first trimester of
pregnancy, when the population of NK cells is abundant, has led
many to speculate about the role NK cells may play in HCMV
control (10). Tilburgs and colleagues have recently demonstrated
distinct cytotoxic responses in dNK cells to HCMV in first
trimester versus at term wherein term pregnancy dNKs harbor
reduced efficacy in responding to HCMV–infected cells (86).
Siewera et al., suggested that dNK cells undergo a phenotypic
transformation to acquire cytotoxic function in the presence of
HCMV-infected cells (80). This study proved, through antibody
mediated abrogation of the Fas ligand (FasL) and tumor necrosis
factor-related apoptosis-induced ligand (TRAIL) on dNK cells,
that death of HCMV infected cells is not initiated by dNK cells
through these death receptor-ligand pathways. However, this
study demonstrated that dNK cells form immunological
synapses with HCMV infected fibroblasts, enabling the delivery
of perforin/granzyme for cellular destruction. Furthermore, the
ability of dNK cells to degranulate in the presence of HCMV
infected fibroblasts was demonstrated to be through high levels
of CD107a expression, a key cell surface molecule in the
mechanism of lytic granule release. dNK cells have also been
found to secrete higher quantities of granulysin when compared
to peripheral blood NK cells. Upon incubation with infected
fibroblast cells, it was noted that CD56bright NK cells decreased
from 76.3% to 48%, while there was an elevation in Cd16
expression by NK cells, denoting a transformation to a
cytotoxic phenotype. HCMV infected cells have been noted to
upregulate expression of natural cytotoxicity receptor (NCRs)
NKp44 by almost 2-fold on dNK cells as well as increasing
expression of NKG2C. NCRs are associated with activation of the
cytotoxic profile of NK cells. Accompanying this was a reduction
in NKG2A, KIR2DL1, KIR2DL4, and ILT2 receptor expression,
receptors aligned with NK effector inhibitory function (76).
Activating dNK cell receptors such as KIR2DS1, KIR2DS2,
KIR2DS5 and KIR3DS1 have been correlated with antiviral
activity (40). A study by Crespo et al., demonstrated an
increased population of KIR2DS1 + NK cells in the decidua,
suggesting an increased activating dNK cell capability in
response to HLA-C2, and thereby increased cytotoxic
potential. These cells also displayed higher levels of cytolytic
molecules when compared to peripheral NK cells. This study
demonstrated that KIR2DS1 + dNK cells showed increased
cytotoxicity to HCMV infected decidual stromal cells (DSCs)
positive for HLA-C2 when compared to KIR2DS1- dNK cells.
This was not the case for infected JEG-3 and primary EVT cells,
which did not appear to initiate degranulation or cytokine
secretion from dNK cells. Despite this, a reduction in the
number of infected EVTs in the presence of co-cultured dNK
cells was noted, suggesting that dNK may be clearing virus
infected EVTs by other means (40). HCMV has been seen to
reduce expression of MHC class I, thereby potentially evading
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CD8+ T cell destruction (87–89). One study reports an initial
reduction in HLA-C expression on EVTs in HCMV infection.
The possible reason for this is not clear, however this study
suggests it could prevent inhibition of NK cells through the
HLA-C/KIR2DL1 route, with an additional suggestion of
potentially other unknown ligands being upregulated for
activation of KIR2DS1, leading to cytotoxic action against
infected cells (40).
Another study showed that the potential effect of dNK cell
activation on T-cell activation could be mediated via an
upregulation in HLA-DR expression upon exposure to HCMV
infected fibroblasts (80). Therefore, dNK cells may play a role in
congenital HCMV infection by potentially protecting the first
trimester fetus from infection via activation of T cell function.
Collectively, these studies indicate varied interactions
between dNK cells and HCMV, with many routes by which
HCMVmay evade clearance as well as a number of ways through
which dNK cells may be activated in the presence of HCMV
infected cells. Additionally, dNK cells are seen specifically to
modulate activity in the context of T cell activation.
ZIKV
Zika Virus (ZIKV) was first isolated in 1947 in Zika Forest,
Uganda, from infected Rhesus monkey serum during
epidemiological yellow fever research (90, 91). However, the
first case of human infection was not reported until 1954, when
three patients presented with jaundice and were later confirmed
to have rising levels of Zika antibodies (92). Initially, ZIKV was
associated with innocuous prodromal illness on the African and
Indian subcontinents transmitted by the Aedes aegyptimosquito,
leading to an asymptomatic or self-limiting course of infection
(93). In 2007, a mild disseminated infection was identified to be
ZIKV in over 70% of the population of the Island of Yap (94).
Concerns regarding human ZIKV infections were not aroused
until 2013 when incidences of neurological deficits associated
with ZIKV infection were first described, with almost 30,000
recorded infections noted in French Polynesia (95, 96). Shortly
following this in 2015, a ZIKV epidemic began in South America
where not only were neurological deficits such as Guillain-Barré
syndrome seen, but also spontaneous abortion and congenital
malformations such as microcephaly in infants from infected
mothers (91). By the end of the 2017 epidemic in Brazil, there
were more than 200,000 notifications of ZIKV cases (97).
Estimates for infants born with congenital Zika syndrome
(CZS) after the 2015-2016 epidemic ranged from 5 to50 in
every 10,000 births (98). The threat of a ZIKV epidemic
lingers, with WHO reporting 61 countries affected by Aedes
aegypti mosquitoes, therefore carrying the potential for ZIKV
infection and transmission (99). ZIKV demonstrated continuing
global epidemic capacity in India in 2018 (100).
ZIKV belongs to the flavivirus family alongside West Nile
virus, Dengue virus, and Yellow fever virus. ZIKV is an
enveloped and icosahedral virus with a nonsegmented, 10.7 kb
single stranded positive sense RNA genomes (101). This virus is
composed of several proteins, categorized as three structural
(capsid, pre-membrane and envelope) and seven nonstructural
proteins. The seven nonstructural proteins (NS1, NS2A, NS2B,
NS3, NS4A, NS4B, and NS5) are essential for viral replication
and assembly, as well as being responsible for the pathogenicity
of the virus by binding to transcription and restriction factors
(95). The biggest risk of congenital ZIKV infection is for mothers
infected during their first trimester (102). ZIKV infection
demonstrates wide tissue tropism, with ZIKV successfully
infecting the central nervous system, blood, retinal, genital and
reproductive tissues including placenta (103–107). ZIKV was
thought to be exclusively arthropod transmitted until cases of
human-human transmission emerged in nonendemic regions,
illustrating a role for sexual transmission (108–110). The
presence of ZIKV RNA has also been found in breast milk of
ZIKV infected mothers (111–113). However, there are reports
which suggest that vertical transmission of ZIKV by breastmilk
does not occur in most cases, which suggests the possibility that
breastmilk does not have a high enough viral load to infect the
newborn (114, 115).
Despite some knowledge regarding ZIKV pathogenesis, its
mechanism of infection in placental immune cell types remains
limited (116–119). Histopathology of ZIKV infected placentae
has shown ZIKV infection in first trimester villous stromal tissue
cells, which includes immune cells in the chorionic villi (117,
120, 121). Uniquely, ZIKV was also found to infect CTBs,
endothelial cells, fibroblasts and HC in chorionic villi, as well
as amniotic epithelial cells and trophoblast progenitor cells (103,
116–118, 122–124) (Figure 4).
ZIKV and HCs
Similar to HCMV, ZIKV has also been shown to infect HCs and
CTBs (90, 116, 117). During the first trimester of pregnancy, ZIKV
infects HCs, entering the fetal blood stream in order to reside in
the placenta. ZIKV uses HCs as a “Trojan Horse”. This strategy is
utilized by several viruses in order to cross the blood brain barrier,
where the virus infects leukocytes, leading to them being carried
across barriers and thereby enabling the propagation and spread of
infection (125–127). HCs have been associated with ZIKV spread
to the fetus through the “Trojan Horse” route (91). The presence
of ZIKV-specific antigen was demonstrated in HCs in confirmed
maternal infection. Multiple studies suggest HCs are a crucial step
in vertical transmission of ZIKV to fetal cells, demonstrating that
HCs are preferentially infected when compared to CTBs (116, 122,
128). Infection of HCs with ZIKV is thought to propagate
infection through hyperplasia and proliferation of these cells,
leading to persistence of this HC population into later trimesters
(116, 122, 128). A study performed on first trimester fetal and
maternal tissue showed that ZIKV can replicate in different cell
types, such as decidual fibroblasts and macrophages. It can also
infect trophoblasts and HCs as well as umbilical cord
mesenchymal stem cells, suggesting that the route of ZIKV
infection may move from the decidua basalis to the anchoring
villi (129). A study performed using blood from 30+ Asian ZIKV
infected pregnant women shows that CD14+ monocytes are the
primary target of ZIKV infection. These monocytes are resistant to
change in M2 phenotype and downregulate type 1 IFN signaling,
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which induces the expression of different host genes involved in
pregnancy complications (130).
In the decidua basalis, ZIKV infects EVTs, macrophages and
stromal cells. ZIKV also targets proliferative CTBs in the
anchoring villi, however is unlikely to infect STBs due to IFN-
l-mediated antiviral defense mechanisms (131). ZIKV achieves
replication within macrophages through FcR, TLR4 and DC-
SIGN receptors (116, 132). In vitro studies have demonstrated
ZIKV infection to be augmented in HCs by IgG from prior
flavivirus exposure through antibody dependent enhancement
(ADE) (133). There remain many gaps in knowledge regarding
the role for macrophages targeted and infected by ZIKV. A study
performed using decidual and chorionic villous tissue from early
and mid-gestation human pregnancy shows that ZIKV appears
to elevate type I and III IFN expression, which does not occur in
HCMV infection (131).
ZIKV and T Cells
Studies looking at the interaction between ZIKV and T cells in
humans are scarce although ZIKV infection has been
demonstrated to activate both CD4 and CD8 T cells (134) with
specific increases in Vd2 TCR+ cells which have been implicated
in recurrent miscarriages but not associated with ZIKV-induced
fetal complications. There have not been notable studies looking
specifically at T cell ZIKV communication at the human
maternal-fetal interface (135). A recent study examined
peripheral T cell responses of 45 confirmed cases of ZIKV
infection that had been stimulated with pooled ZIKV peptides
from all viral components (136). This study demonstrated
responses from both CD4+ and CD8+ T cells to both
structural and nonstructural ZIKV components. However,
this study particularly showed that CD4+ T cells exhibited a
strong response to nonstructural proteins NS1, NS3 and NS5,
and CD8+ T cells a strong response to cap and env proteins. This
response was demonstrated by marked IFN-g production from
both cell subtypes indicating cell activation (136).
Another case looking at a ZIKV infected individual from the
United States demonstrated interactions between the ZIKV NS2
and env proteins with CD4+ and CD8+ T cells, respectively.





FIGURE 4 | Interactions between Zika virus (ZIKV) and immune cells at the maternal-fetal interface. (A) ZIKV infects Hofbauer cells (HCs) and is thought to achieve
replication through Fc, TLR4 and DC-SIGN receptors, which in turn increases secretion of type I and III interferons. (B) ZIKV infection of fetal trophoblasts and
fibroblasts occurs through FcgR and results in increased expression of some interferons, such as IFNa, and decreased expression of others, such as IFN-g and IFN-
b. Infection is associated with increased secretion of proinflammatory cytokines such as IP-10, IL-6, and MCP-1. NS5 viral proteins are thought to downregulate
interferon-stimulated genes (ISGs) and reduce interferon signaling via STAT2 degradation, while the viral proteins NS1 and NS4B inhibit IFN signaling by
downregulating TBK1. (C) CD4+ T cells exhibit a strong response to nonstructural NS1, NS3, and NS5 ZIKV proteins, while CD8+ T cells respond to cap and env
ZIKV proteins. In both cases, response to ZIKV proteins was characterized by increased IFN-g production. (D) Systemic dNK cells exhibit increased activation,
including increased IFNg production and CD107a expression when incubated with ZIKV infected monocytes.
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ZIKV infected individuals showed activity in response to
nonstructural proteins (NS1, NS3 and NS5). Consistently, CD8+
T cells were seen to raise activity against the structural protein env
(138, 139). These studies demonstrate consistency in the response
of CD4+ T cells and CD8+ T cells to ZIKV proteins, revealing
CD4+ T cells to specifically respond to particular nonstructural
proteins and CD8+ T cells to react to structural proteins,
particularly cap and env (136, 138, 139).
Several studies have looked at the ability of DENV-specific
CD4+ and CD8+ T cells to be stimulated by the presence of
ZIKV peptides in humans (140, 141). These studies showed viral
epitopes for specific peptides located in similar regions and
structurally conserved across flaviviruses; however, they
displayed differences in their sequences (141). Nonetheless,
these studies indicated cross-reactivity between the viruses
regarding their CD4+ and CD8+ T cell activity. One study
demonstrated that CD8+ and CD4+ T cells from DENV
positive donors reacted to ZIKV viral peptides, resulting in an
upregulation of IFNg secreting cells. This group also showed that
stimulation with ZIKV peptides for those in acute phase of ZIKV
infection resulted in recruitment of elevated levels of CD8+ IFN-
g+ T cells (142).
A recent transcriptomics study investigated transcriptional
signatures in CD4/CD8 T cells, B, and NK cells and plasmacytoid
dendritic cells in patients (nonpregnant) infected with ZIKV
(143). Interestingly, they did not note significance transcriptional
changes in NK or CD8 T cells in a ZIKV infected background but
noted significance alterations in pDCs. Whether pregnancy plus
ZIKV infection would affect the immune cell transcriptome in
humans remains to be determined.
ZIKV and Peripheral NK Cells
Studies specifically analyzing interactions between dNK cells and
ZIKV in humans once again are lacking. However, studies have
looked at ZIKV and its communication with peripheral NK cells.
One such study postulated crosstalk between monocytes and NK
cells in ZIKV infected patients. The activation of NK cells was
associated with the presence of monocytes, which induced
expression of IFN-g and CD107a, key markers of NK cell
function. Depletion of monocytes in the peripheral blood
reduced the levels of these markers and thus the activation of
NK cells (144). There are few studies showing the interaction
between ZIKV with NK cells. Glasner et al., showed that ZIKV
infection led to activation ofMHC class I, which was somehow not
sensed by dNK cells and their activating receptors, allowing the
virus to escape NK cell-mediated killing. MHC class I expression is
triggered through the IFN-b pathway via activation of RIGI-IRF3
(145). However, the mechanism by which NK cells may promote
an immunosuppressive environment in the face of ZIKV infection
is not clear. Some studies have indicated that interactions between
other aspects of the innate immune system and NK cells may be at
play in ZIKV pathogenesis.
ZIKV and Innate Immunity
There are several studies suggesting that pathogenesis of ZIKV
is not mediated through decidual immune cells alone but rather
conducted, at least in part, through the activation of interferon-
stimulated genes (ISGs), which in turn leads to activation of
innate host cell immunity (131). ISGs act to specifically target
viral replication. Multiple studies have indicated ZIKV
stimulation of interferons (IFN) to vary depending on the
type of IFN. While type I and III IFNs have been shown to be
inhibited by ZIKV, specifically the NS5 component of the
pathogen, Type II IFNs have been shown to be upregulated
by the virus (146, 147). One study demonstrated that when
Type III IFNs were upregulated, specifically IFN-l1,
trophoblast cells were infected with ZIKV at a lower rate.
Further, NS1, NS4A and NS4B have been demonstrated to
inhibit IFN type I response. This leads to suppression of the
TANK binding kinase 1 (TBK1)/IRF3 and JAK-STAT pathway,
which in turn results in reduced activation of innate immune
responses (148).
Interferon induced transmembrane protein 1 (IFITM1) and
IFITM3 specifically are ISGs which act as restriction factors to
inhibit ZIKV replication. The mechanism by which the
inhibition and activation of innate immunity impacts the
recruitment of innate immune cells to the site of infection is
not clear. Little is known about the role of NK cells in human
ZIKV infection. One study has noted interactions between TLR7,
CD81 and IFITM1, postulating that the restriction of ZIKV is
associated with inhibitory activity of IFITM1, potentially
through activation of NK cells (149, 150). Another group
looking at ISGs showed that viperin played a role in ZIKV
pathogenesis, with data revealing that when viperin levels were
high, ZIKV mRNA levels were low and vice versa (148). NS4 is
seen to target directly the Akt-mTOR pathway, leading to
reduced signaling from this pathway and subsequent activation
of autophagy in host cells (151). ZIKV has been shown to co-opt
the autophagy pathway for post-RNA replication capacity and
survival (152, 153). Importantly, the NS2B-NS3 protease activity
of ZIKV can be blocked by an inhibitor of autophagy,
hydroxychloroquine (HCQ) (154). HCQ is an FDA approved
drug considered safe to use during pregnancy and could serve as
an effective treatment for preventing ZIKV congenital
syndrome (124).
The relationship between ZIKV infected cells and attenuated
IFN production has been extensively reported, leading to
questions regarding the mechanism underlying this association.
It has been proposed that ZIKV may infect cells through ADE of
infection. Many cells express the Fcg receptor, and it is thought
that viral particles may complex with antibodies and thereby
enter into cells via Fcg receptors (133). Host cells (such as
trophoblasts and fibroblasts) infected with ZIKV demonstrate
innate immune system activation with a rise in specific IFNs (e.g.
IFN-a), but falling levels of others such as IFN-l1 and IFN-b
(155). The elevated levels of proinflammatory cytokines and
chemokines, namely IL-6, MCP-1 and IP-10 which are linked to
recruitment of immune cells such as monocytes and T cells
(155). ZIKV has been shown in multiple studies to downregulate
type I IFN signaling and to be active in suppression of antiviral
signaling. ZIKV nonstructural proteins NS1 and NS4B inhibit
IFN signaling by downregulating levels of TBK1. However,
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NS2B3 downregulates the JAK-STAT pathway and inhibits
apoptosis of ZIKV, and hence inhibits innate antiviral
responses (150). One study specifically has implicated the role
of the nonstructural ZIKV protein NS5 in promoting ZIKV
propagation by targeting STAT2 for degradation, thereby
reducing ISG levels (156). This is thought to promote viral
replication through a dampened host innate immune cell
response. There remains much to be elucidated in terms of
ZIKV infection in human pregnancy. New studies are identifying
metabolic reprogramming pathways underpinning innate
immune responses to ZIKV which opens additional avenues of
investigation (157). We refer readers to recent reviews
highlighting ZIKV-immune interactions in adverse pregnancy
outcomes (119) and ADE (158).
New Tools to Study Viral Interactions at
the Maternal-Fetal Interface in Human
Pregnancy: Placenta-on-a-Chip
and Organoids
The limited availability of placental tissues during early
pregnancy has always been a challenge for the reproductive
biologists, hampering the study of placental physiology and cell
to cell interactions. In vitro cell line models can often be
biologically distinct and therefore unable to demonstrate
enough similarity to replicate the conditions of human
pregnancy. In addition, the use of cell line models can fail to
reproduce the complexity of the number of cell types and cell
interactions present within the decidua. Therefore, functional in
vitro 3D models being are developed, for example placenta-on-a
chip and organoid cultures, which can mimic in vivo conditions
and would be useful to understand the mechanisms of viral
host interactions.
The ‘Placenta-on-a-chip’ is a microfluidics model utilizing
human trophoblast cells (BeWo) and fetal derived cells
(HUVECs and HPVECs) (159, 160). These cell lines are
cultured and separated by a semipermeable membrane within
flow conditions with the purpose of understanding placental
mechanisms and barrier function (159). Recent reports have
described the faithfulness of placenta-on-a-chip model to in vivo
placental conditions (161). For example, glucose transport using
a placenta-on-a-chip model was demonstrated by Lee et al., and
Blundell et al., highlighting significant similarity to in
vivo glucose transport in the human placenta (159, 160).
Placenta-on-a-chip models have also been used to investigate
the transport of heparin and anti-hyperglycemic agents such as
glyburide using BeWo and human placental villous endothelial
cells (162). Recently, the transport of the xenobiotic compound
caffeine across the placenta has been studied using this model
system, providing new insights into the extent of caffeine transfer
from mother to fetus (163).
Bacterial infections have also been studied using this model.
Zhu et al., showed that in the presence of Escherichia coli (E. coli),
trophoblast cells (BeWo) activated the circulating macrophages
on the “maternal” side of the chip to secrete several inflammatory
cytokines that mimicked in vivo conditions during pregnancy
(164). The impact of common environmental exposures such as
titanium dioxide nanoparticles (TiO2-NPs) has also been studied
using this 3D placental model showing a series of different
placental responses (barrier permeability, oxidative stress, cell
apoptosis, and maternal immune cells behavior (165). They
showed placental barrier permeability and maternal immune
cells to be influenced by even low concentration of NPs (165).
Therefore, this simple in vitro model can prove useful in
understanding the environmental exposure of NPs during
pregnancy and can help in a range of biological studies (165).
Recent studies report generation of an organ-on-a-chip model,
wherein decidualized human endometrial stromal cells and
macrophage cell lines are co-cultured in a microfluidic device
and shown to inhibit secretion of TNF-a in response to LPS
stimulation (166). These devices have also been used to
determine the impact of cytokine secretion by dNK cells on
the migration of primary trophoblast cells. These studies
illustrate the functionality of microfluidic organ on chip
devices to elucidate importance of maternal immune cells in
the placenta (167). Thus, the use of fetal membrane on organ-on-
a-chip provides a suitable model to explore the impact of
pathogenic infections during pregnancy (168, 169).
The use of in vitro trophoblast organoids as a 3D culture
model also provides a new tool to understand the mechanism of
implantation at the maternal-fetal interface. Recent studies have
shown the characterization of these organoids derived from 1st-
trimester CTBs (6 to 8 weeks) and suggest their resemblance to
primary trophoblast cells (170–172). Due to similarity with the
placental architecture, these organoids could be used to study
physiological, metabolic and hormonal changes that
occur during pregnancy.
The viruses we highlighted in this review, HCMV and ZIKV,
do not naturally infect commonly used animal models [e.g., mice]
which makes it challenging to understand disease pathogenesis.
In particular, there remains a paucity of understanding
ZIKV-immune cell interactions during pregnancy. Thus, the
employment of placenta-on-a-chip or organ-on-a-chip, and
organoid models will be pivotal in providing functional and
physiologically relevant ways to study the interaction of immune
cells at the maternal-fetal interface with viral pathogens that
affect pregnancy.
SUMMARY
Both HCMV and ZIKV can be sequestered into fetal
macrophages. HCMV implicates HCs in the potential infection
of other decidual cells, leading to the promotion of HCMV
transcytosis in trophoblasts. ZIKV preferentially infects HCs,
persisting in this cell population and potentially mediating
infection of other fetal-derived cells. More poignant is the
suggestion that decidual macrophages may mediate reactivation
of HCMV by acting as a latent reservoir for infection. These
studies collectively indicate a central role for macrophages in the
pathogenesis of TORCH viruses.
dNK cells have been seen to alter their phenotype to express
higher levels of various activating receptors when in the presence
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of infected decidual fibroblast cells. They also are known for their
plasticity in the face of specific pathogens, acquiring more cytotoxic
function. KIR2DL1/HLA-C2 has been identified as a mechanism
by which dNK cells are activated and display cytoxicity toward
HCMV infected cells. It has also been suggested that dNK cell
activation may trigger activation of T-cells through upregulating
HLA-DR expression on infected fibroblast cells.
ZIKV viral components demonstrate capacity to elicit strong
responses from peripheral CD4+ and CD8+ T cells, with NS1,
NS3, and NS5 being associated with CD4+ stimulation whereas
Cap and Env proteins being associated with CD8+. We also see
in this review the importance of Interferon stimulating genes in
the restriction of ZIKV replication.
Thus, the implications and outcomes of viral interactions with
immune cells at the maternal-fetal interface are varied. We see the
importance of the host immune response and recognize the
importance of studying mechanisms of pathogenesis in detail to
enable targeted therapeutic interventions including vaccines to
mitigate the adverse outcomes of viral infections during pregnancy
(Figure 5). Finally, we posit that better understanding of the
immunological underpinnings of infections at the maternal fetal
interface can support the inclusion of pregnant women in trials
testing vaccines and therapeutics to compact existing and
emerging viral infections.
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FIGURE 5 | Summary of interactions between viruses and immune cells at the maternal-fetal interface. Human cytomegalovirus (HCMV) preferentially infects
Hofbauer cells (HCs) and increases cytotoxicity of decidual Natural Killer (dNK) cells but decreases activation of decidual T cells. Zika virus (ZIKV) preferentially infects
HCs and decreases cytotoxicity of dNK cells and increases activation and IFNg secretion in decidual T cells.
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Peralta JM. Zika virus shedding in human milk during lactation: an unlikely
source of infection? Int J Infect Dis (2017) 57:70–2. doi: 10.1016/
j.ijid.2017.01.042
112. Blohm GM, Lednicky JA, Márquez M, White SK, Loeb JC, Pacheco CA, et al.
Evidence for Mother-to-Child Transmission of Zika Virus Through Breast
Milk. Clin Infect Dis (2018) 66:1120–1. doi: 10.1093/cid/cix968
113. Dupont-Rouzeyrol M, Biron A, O’Connor O, Huguon E, Descloux E.
Infectious Zika viral particles in breastmilk. Lancet (2016) 387:1051. doi:
10.1016/S0140-6736(16)00624-3
114. Mann TZ, Haddad LB, Williams TR, Hills SL, Read JS, Dee DL, et al.
Breast milk transmission of flaviviruses in the context of Zika virus:
A systematic review. Paediatr Perinat Epidemiol (2018) 32:358–68. doi:
10.1111/ppe.12478
115. Colt S, Garcia-Casal MN, Peña-Rosas JP, Finkelstein JL, Rayco-Solon P,
Weise Prinzo ZC, et al. Transmission of Zika virus through breast milk and
other breastfeeding-related bodily-fluids: A systematic review. PloS Negl Trop
Dis (2017) 11:e0005528. doi: 10.1371/journal.pntd.0005528
116. Quicke KM, Bowen JR, Johnson EL, McDonald CE, Ma H, O’Neal JT, et al.
Zika Virus Infects Human Placental Macrophages. Cell Host Microbe (2016)
20:83–90. doi: 10.1016/j.chom.2016.05.015
117. Tabata T, Petitt M, Puerta-Guardo H, Michlmayr D, Wang C, Fang-Hoover J,
et al. Zika Virus Targets Different Primary Human Placental Cells, Suggesting
Two Routes for Vertical Transmission. Cell Host Microbe (2016) 20:155–66.
doi: 10.1016/j.chom.2016.07.002
118. Simoni MK, Jurado KA, Abrahams VM, Fikrig E, Guller S. Zika virus
infection of Hofbauer cells. Am J Reprod Immunol (2017) 77. doi: 10.1111/
aji.12613
119. Teixeira FME, Pietrobon AJ, Oliveira LM, Oliveira L, Sato MN. Maternal-
Fetal Interplay in Zika Virus Infection and Adverse Perinatal Outcomes.
Front Immunol (2020) 11:175. doi: 10.3389/fimmu.2020.00175
120. Petitt M, Tabata T, Puerta-Guardo H, Harris E, Pereira L. Zika virus
infection of first-trimester human placentas: utility of an explant model of
replication to evaluate correlates of immune protection ex vivo. Curr Opin
Virol (2017) 27:48–56. doi: 10.1016/j.coviro.2017.11.008
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